Protagonist Therapeutics (PTGX)
(Delayed Data from NSDQ)
$34.02 USD
-0.01 (-0.03%)
Updated Jun 6, 2024 04:00 PM ET
After-Market: $34.04 +0.02 (0.06%) 6:00 PM ET
3-Hold of 5 3
D Value D Growth B Momentum D VGM
Brokerage Reports
Protagonist Therapeutics, Inc. [PTGX]
Reports for Purchase
Showing records 41 - 49 ( 49 total )
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Early Phase 2 Results Make Polycythemia Vera the Focus for PTG-300
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Some Patience Is Needed, But Three Assets Moving Towards Phase 3
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
PD Data Robust; But We Still Await Clinical Proof of Concept
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Let''s Not Jump to Conclusions on PTG-300; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Takeaways From Our Coverage at the Global Investment Conference
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
PN-943 Continues to Look Promising; Reiterating Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D